Health Catalyst (HCAT) Expected to Announce Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Health Catalyst to post earnings of $0.11 per share and revenue of $79.59 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Health Catalyst Stock Down 0.4 %

Health Catalyst stock opened at $5.40 on Wednesday. The stock has a market capitalization of $328.59 million, a PE ratio of -4.00 and a beta of 1.34. Health Catalyst has a twelve month low of $5.32 and a twelve month high of $9.89. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average of $6.41 and a 200-day moving average of $7.32.

Insiders Place Their Bets

In other news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the transaction, the insider now directly owns 236,950 shares of the company’s stock, valued at $2,118,333. This represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Linda Llewelyn sold 6,442 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96. Following the completion of the transaction, the insider now directly owns 98,702 shares in the company, valued at $777,771.76. The trade was a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,169 shares of company stock valued at $629,068. 2.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on HCAT shares. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research report on Wednesday, January 8th. Royal Bank of Canada cut their price objective on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 15th. Stephens boosted their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 14th. Piper Sandler cut their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group cut their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.20.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.